Akari Therapeutics (NASDAQ:AKTX) Downgraded by Maxim Group to Hold

Maxim Group downgraded shares of Akari Therapeutics (NASDAQ:AKTX) from a buy rating to a hold rating in a research report released on Wednesday morning, MarketBeat Ratings reports.

Several other research analysts have also recently weighed in on AKTX. HC Wainwright boosted their target price on Akari Therapeutics to $27.00 and gave the stock a “buy” rating in a report on Wednesday, April 1st. LADENBURG THALM/SH SH started coverage on Akari Therapeutics in a report on Monday, January 5th. They set a “buy” rating and a $40.00 target price on the stock. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Akari Therapeutics in a report on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $89.00.

Akari Therapeutics Trading Up 2.1%

NASDAQ:AKTX opened at $3.88 on Wednesday. Akari Therapeutics has a 12 month low of $3.25 and a 12 month high of $63.20. The stock has a 50 day moving average of $8.12 and a two-hundred day moving average of $16.88.

Akari Therapeutics (NASDAQ:AKTX) last posted its quarterly earnings data on Monday, March 30th. The biopharmaceutical company reported ($2.68) EPS for the quarter, missing the consensus estimate of ($0.03) by ($2.65).

Institutional Trading of Akari Therapeutics

An institutional investor recently bought a new position in Akari Therapeutics stock. Armistice Capital LLC acquired a new stake in Akari Therapeutics PLC (NASDAQ:AKTX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned approximately 5.95% of Akari Therapeutics at the end of the most recent reporting period. 5.06% of the stock is currently owned by hedge funds and other institutional investors.

Akari Therapeutics Company Profile

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.